March 2022 "Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in immunoresistance development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte

interconnected nodes which learn hierarchical representations of the data, eliminating the need for explicit

Dosing of First Participant with Metabolic Syndrome in Phase 1B Clinical Trial Domain Therapeutics and Explicyte

Sexually Explicit Material ​ Do not distribute sexually explicit or pornographic material.